FDA Considers Noninvasive Endpoint for MASH Trials, Boosts Biotech Shares on August 28, 2025 Altimmune Biological Markers Clinical Trials Inventiva Liver diseases Madrigal Pharmaceuticals MASH Noninvasive Endpoint stocks United States Food and Drug Administration Viking Therapeutics +
Inventiva Slashes Workforce and Pipeline to Focus on MASH Drug Lanifibranor on February 11, 2025 Inventiva lanifibranor MASH Phase 3 Trial pipeline restructuring +